Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Medicamen Organics Ltd. Share Price
Day's Range
Low
₹0.00
High
₹0.00
Price Summary
| Previous Close | ₹26.50 |
|---|---|
| Day's Range | ₹0.00 - ₹0.00 |
| Open | ₹0.00 |
| 52 Week Range | ₹19.10 - ₹34.00 |
| Volume | 0 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -2.70 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 1.03 |
| PAT Margin (%) | -17.76 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -10.38 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | N/A | 370.88 |
| Expenses | N/A | N/A |
| PBT | N/A | 43.87 |
| Operating profit | N/A | 0.0 |
| Net profit | N/A | 32.71 |
About Medicamen Organics Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | Bal Kishan Gupta |
| NSE Symbol | MEDIORG |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,26,661.74 | 1,770.70 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,57,902.73 | 9,955.95 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,76,306.21 | 4,590.00 | 3,532.60 - 3,532.60 |
| Laurus Labs Ltd. | 1,29,242.68 | 2,372.10 | 917.95 - 917.95 |
| Zydus Lifesciences Ltd. | 1,24,089.48 | 1,237.00 | 835.50 - 835.50 |
| Apollo Hospitals Enterprise Ltd. | 1,20,779.11 | 8,443.30 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,17,959.74 | 670.00 | 0.00 - 0.00 |
| Dr. Reddy's Laboratories Ltd. | 1,12,698.53 | 1,355.85 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,11,488.55 | 1,378.80 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,02,796.60 | 2,490.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
IOL Chemicals and Pharmaceuticals submits investor presentation
IOL Chemicals and Pharmaceuticals submits newspaper publication
Pursuant to the Regulation 47 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, IOL Chemicals and Pharmaceuticals has informed that it enclosed copies of the newspaper publication of un-audited Financial Results for the quarter and half year ended 30th September 2026 published in Business Standard, Economic Times, Financial Express, and Punjabi Jagran on 31st October 2026.
The above information is a part of company’s filings submitted to BSE.
Hikal informs about press release
Tejnaksh Healthcare informs about disclosure
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Tejnaksh Healthcare has informed that, Dr. Ashish V. Rawandale-Patil, Managing Director of the company, has been selected as a Mentor for the Technology Innovation Program 2027 (ES-TIP 2027) of the Endourological Society, a globally recognized international organization in the field of urology. The Technology Innovation Program aims to support and mentor medical innovations and assist healthcare professionals in developing novel ideas for improving patient care, with promising innovations being considered for further development and commercialization. Dr.Ashish Rawandale-Patil has been selected as one of the mentors for the program and is the only urologist from outside the United States to join three other distinguished mentors from leading institutions in the United States. This recognition reflects his contribution to medical innovation and highlights India's growing presence on the global healthcare innovation platform. The Company believes that this prestigious international recognition enhances the reputation and visibility of Tejnaksh Healthcare and showcases the global expertise and leadership associated with the Company.
Advanced Enzyme Tech - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 1371.68 | 1157.48 | 18.51 | 2530.25 | 2407.72 | 5.09 | 4527.66 | 3514.11 | 28.84 |
| Other Income | 163.97 | 30.79 | 432.54 | 186.84 | 569.31 | -67.18 | 633.88 | 614.90 | 3.09 |
| PBIDT | 543.16 | 326.70 | 66.26 | 870.15 | 1170.48 | -25.66 | 1738.22 | 1321.69 | 31.51 |
| Interest | 0.31 | 0.49 | -36.73 | 0.68 | 1.02 | -33.33 | 2.07 | 2.36 | -12.29 |
| PBDT | 542.85 | 326.21 | 66.41 | 869.47 | 1169.46 | -25.65 | 1697.57 | 1319.33 | 28.67 |
| Depreciation | 31.73 | 30.02 | 5.70 | 60.94 | 59.31 | 2.75 | 120.83 | 114.05 | 5.94 |
| PBT | 511.12 | 296.19 | 72.56 | 808.53 | 1110.15 | -27.17 | 1576.74 | 1205.28 | 30.82 |
| TAX | 94.07 | 73.37 | 28.21 | 168.02 | 147.52 | 13.90 | 258.68 | 181.08 | 42.85 |
| Deferred Tax | 1.25 | 0.54 | 131.48 | 8.56 | 0.28 | 2957.14 | -12.01 | 12.22 | -198.28 |
| PAT | 417.05 | 222.82 | 87.17 | 640.51 | 962.63 | -33.46 | 1318.06 | 1024.20 | 28.69 |
| Equity | 220.53 | 223.76 | -1.44 | 223.95 | 223.76 | 0.08 | 223.85 | 223.76 | 0.04 |
| PBIDTM(%) | 39.60 | 28.23 | 40.29 | 34.39 | 48.61 | -29.26 | 38.39 | 37.61 | 2.07 |
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Medicamen Organics Ltd. is ₹26.50 as of 2026-11-02.
The market capitalisation of Medicamen Organics Ltd. is ₹39.43 as of 2026-10-30.
The 1-year return of Medicamen Organics Ltd. is -6.90% as of 2026-11-02.
The P/E ratio of Medicamen Organics Ltd. is 0.00 as of 2026-11-02.
The 52-week high and low of Medicamen Organics Ltd. are ₹34.00 and ₹19.10, respectively, as of 2026-11-02.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
